Use of artificial intelligence-guided echocardiography to detect cardiac dysfunction and heart valve disease in rural and remote areas: Rationale and design of the AGILE-echo trial.

Journal: American heart journal
PMID: 39128659

Abstract

BACKGROUND: Transthoracic echocardiography (TTE) is essential in the diagnosis of cardiovascular diseases (CVD), including but not limited to heart failure (HF) and heart valve disease (HVD). However, its dependence on expert acquisition means that its accessibility in rural areas may be limited, leading to delayed management decisions and potential missed diagnoses. Artificial intelligence-guided (AI)-TTE offers a solution by permitting non-expert image acquisition. The impact of AI-TTE on the timing of diagnosis and early initiation of cardioprotection is undefined.

Authors

  • Cheng Hwee Soh
    Imaging Research, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Victoria, Australia.
  • Leah Wright
    Baker Heart and Diabetes Institute, Melbourne, Australia.
  • Angus Baumann
    Alice Springs Hospital, The Gap, Northern Territory, Australia.
  • Bastian Seidel
    Ochre Medical Centre, Hobart, Tasmania, Australia.
  • Christopher Yu
    Carnegie Mellon University, Pittsburgh, Pennsylvania, USA.
  • Mark Nolan
    Imaging Research, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Tony Mylius
    Merredin District Hospital, Western Australian Country Health Service, Wheatbelt, Western Australia, Australia.
  • Thomas H Marwick
    Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.

Keywords

External Resources

Popular Topics
Recent Journals